ABSTRACT -Cardiac ischemia-reperfusion stimulates the renin-angiotensin system (RAS) associated with elevated levels of circulating angiotensin II. Numerous studies demonstrate that the antagonist for the angiotensin II type 1 receptor, losartan improves cardiac function in animal models of ischemia-reperfusion. Molecular mechanisms of the cardioprotective effects of RAS inhibitors on cardiac ischemia-reperfusion remain poorly understood, and are not associated with the anti-hypertensive action of these drugs. This Commentary focuses on the study published in the Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18:112-123, that elucidates the role of SIRT3 in the cardioprotective action of losartan against ischemic-reperfusion injury. We provide comprehensive discussion of the role of mitochondria in the cardioprotective effects of losartan through SIRT3.
Cardiac ischemia-reperfusion (IR) is known to stimulate the renin-angiotensin system (RAS) that may have deleterious effects on heart metabolism and function ( Figure 1 ). Activation of RAS during myocardial infarction and ischemic heart disease is associated with elevated levels of circulating angiotensin II (AngII) (1) . Also, activation of cardiac RAS in the ischemic myocardium increases intracellular synthesis of AngII that together with circulating AngII exert detrimental effects on cardiac function through autocrine and paracrine mechanisms (2) . Notably, short-term treatment with AngII exerts cardioprotective effects on IR similar to those induced by ischemic preconditioning in isolated Langendorff-perfused hearts (3) . The deleterious effects of AngII on the ischemic myocardium are mediated through AngII type 1 (AT1) receptors and include suppression of contractility, arrhythmias, alterations of Ca 2+ homeostasis and energy metabolism, increased reactive oxygen species (ROS) generation, etc. (4). Consequently, inhibition of AngII production or action in tissues, constitute important therapeutic strategies to protect the heart against IR. Indeed, both angiotensin-converting enzyme (ACE) inhibitors (5), and AT1 receptor blockers have been shown to exert cardioprotection against IR injury (6) . Several studies demonstrate that the AT1 receptor antagonist, losartan improves cardiac function in the isolated Langendorff-perfused heart subjected to global IR (7), as well as in in vivo models of IR induced by coronary artery ligation (8) . Notably, the cardioprotective effects of RAS inhibitors on cardiac IR are not associated with the anti-hypertensive action of these drugs (9) . Despite the high number of studies available so far, the molecular mechanisms of cardioprotection by RAS inhibition remain unknown. Although blockade of AT1 receptors improves post-ischemic recovery, prevents arrhythmia, increases Ca 2+ storage in the sarcoplasmic reticulum, reduces ROS, and attenuates mitochondrial dysfunction, a cause-effect relationship between these effects has not been established. The article by Klishadi and co-authors published in the Journal of Pharmacy and Pharmaceutical Sciences (10) attempts to establish a role for SIRT3 in the cardioprotective action of losartan following IR injury. The authors demonstrated that pre-treatment of rats with losartan (10 mg/kg/day) for 4 weeks significantly improved the recovery of hearts after in vivo IR induced by coronary artery ligation (30 min) and subsequent reperfusion (120 min). They found that electrical heart abnormalities (ventricular tachycardia and ectopic beats) after IR were _________________________________________ attenuated by losartan, a finding that was associated with increased SIRT3 protein levels. The authors concluded that chronic administration of losartan at non-hypotensive levels, could exert cardioprotection in part, through normalization the SIRT3 protein level in the ischemic myocardium (10) . However, the involvement and role of mitochondrial SIRT3 in these cardioprotective effects of losartan were not considered, limiting the interpretation of the data. Sirtuins are class III histone deacetylases that depend on NAD + for their activity, and play an essential role in the regulation of protein activity by deacetylation. There are seven sirtuin isoforms (SIRT1-7) which subcellular localization varies between the cytoplasm (SIRT2), nucleus (SIRT1, 6, 7) and mitochondria (SIRT3, 4, 5) (11). Proteomic analysis has identified 277 lysine acetylation sites on 133 mitochondrial proteins, thereby establishing that lysine acetylation is an abundant posttranslational modification in mitochondria (12) . Most lysineacetylated proteins (~100 proteins) from mitochondrial fractions were metabolic enzymes involved in various aspects of energy metabolism, including the TCA cycle, fatty acid oxidation, and oxidative phosphorylation (13) . SIRT3 is the main mitochondrial sirtuin isoform that plays a central role in fatty acid oxidation and ATP synthesis in cells (14) . Its expression decreases with age, and neurodegenerative, cardiovascular and metabolic diseases. The study by Klishadi et al (10) did not evaluate mitochondrial function and/or acetylation of mitochondrial proteins in losartan-pretreated versus untreated rats subjected to IR. Also, lack of data on the enzymatic activity of SIRT3 in mitochondria obscures the contribution of SIRT3 to losartan-induced cardioprotection in the ischemic myocardium.
We have previously shown (14) that pretreatment of rats with the direct renin inhibitor, aliskiren (50 mg/kg/day) improved cardiac function after permanent coronary artery ligation for four weeks. The beneficial effects of aliskiren were associated with the improved respiratory function of mitochondria and inhibition of mitochondrial permeability pore (PTP) opening. Interestingly, hearts of aliskiren-treated rats demonstrated high SIRT3 levels and decreased acetylation of mitochondrial proteins including cyclophilin D (CyP-D), a key regulator of PTP formation (15) . These data suggest that chronic inhibition of RAS could exert cardioprotective actions through inhibition of PTP formation by SIRT3-mediated deacelylation of CyP-D.
Chronic blockade of AT1 receptors with losartan could also reduce damaging autocrine/paracrine effects of AngII on coronary arteries and myocardium. Losartan-induced vasodilatation could improve oxygen and substrate delivery to the ischemic myocardium at reperfusion. In addition, inhibition of AT1 receptor by losartan could prevent ROS accumulation by NADH-oxidase (4), inducible nitric oxide synthase (iNOS) (16) and mitochondria (17, 18) are the main inducers of mitochondrial PTP, reductions in their levels by losartan following IR could prevent pore opening and improve mitochondrial function and ATP production. The latter could lead to a reduction in the AMP to ATP ratio and stimulation of AMP kinase (AMPK), a serine/threonine kinase that acts as a "fuel sensor" and regulates energy metabolism in the heart. Activation of AMPK is known to stimulate ATP synthesis, glucose transport, glycolysis and fatty acid oxidation, and inhibits energy-consuming anabolic pathways such as protein synthesis (20) . Indeed, we have shown that losartan enhanced AMPK phosphorylation in AngII-treated cardiomyocytes (17) . Losartan-induced activation of AMPK could upregulate SIRT3 activity through changes in the NAD + /NADH ratio that is the main regulator of sirtuins. AMPK-dependent increases in protein expression of SIRT3 and manganese superoxide dismutase (MnSOD) were found in the mouse skeletal muscle (21) . Interestingly, the beneficial effects of SIRT3 can be mediated through a direct upregulation of antioxidant capacity of cardiomyocytes. SIRT3 has been shown to induce deacetylation and translocation of the forkhead box O3 (FoxO3), a transcription factor, to the nucleus, where it activates antioxidant-encoding genes such as MnSOD and catalase, thereby decreasing cellular levels of ROS (22) . Also, SIRT3 can stimulate PGC-1α and its downstream targets that regulate mitochondrial biogenesis and play a crucial role in cardiac diseases (23) .
It is likely that acetylation of CyP-D due to downregulation of SIRT3 facilitates its interaction with the PTP complex and stimulate pore opening leading to mitochondria-mediated cell death and cardiac dysfunction. A causal role of CyP-D acetylation induced by downregulation of SIRT3 in mitochondrial PTP opening was demonstrated previously (24) . As mentioned above, aliskiren prevented CyP-D acetylation that was associated with upregulation of SIRT3 expression and PTP inhibition in post-infarction rat hearts (15) . Notably, the beneficial effects of losartan on mitochondria can also be mediated through AngII receptors present in mitochondria. We (15) and others (25) reported the expression of AT1 and Ang II type 2 (AT2) receptors in cardiac and kidney mitochondria. In addition, a role for AT2 receptor activation in losartan-mediated cardioprotection cannot be excluded in the setting of RAS activation. This point needs to be evaluated. In addition to acetylation of CyP-D due to downregulation of SIRT3, cardiac IR can activate CyP-D through its interaction with the peroxisome proliferator-activated receptor alpha (PPARα). We have recently shown that the PPARα/CyP-D was associated with PTP opening in cultured cardiomyocytes subjected to oxidative stress [26] and in vivo cardiac IR [27] . Activation of AMPK by metformin abrogated the interaction and prevented PTP opening in both cases.
In conclusion, the study presented by Klishadi and coauthors (10) is an interesting study that attempts to elucidate the role of AngII/AT1 receptors/SIRT3 pathway in losartan-induced cardioprotection against IR injury. This report together with previous studies indicates the importance of mitochondria in attenuation of cardiac dysfunction by the chronic use of RAS inhibitors in response to oxidative stress.
